文献速递其他结缔组织病

来氟米特/羟氯喹联合治疗靶向干燥综合征患者I型干扰素相关蛋白,显示可预测和监测临床反应的潜力

Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren's syndrome that show potential to predict and monitor clinical response.
PubMed 文献 · RMD Open · 2023-01-01

在21例接受来氟米特/羟氯喹(LEF/HCQ)和8例接受安慰剂的原发性干燥综合征患者中,LEF/HCQ治疗24周后IFN特征下降,但与疾病活动度变化相关性差;基线Galectin-9及循环MxA和Galectin-9的下降与临床反应稳健相关,血清Galectin-9早期变化预测24周临床反应的AUC为0.90。

要点

  • LEF/HCQ治疗24周后外周血单个核细胞和全血IFN特征下降,但与疾病活动度变化相关性差。
  • 基线Galectin-9蛋白浓度及循环MxA和Galectin-9的下降与临床反应稳健相关。
  • 血清Galectin-9早期变化预测24周临床反应,AUC为0.90。

核心结论

  • LEF/HCQ联合治疗靶向I型IFN相关蛋白,与B细胞过度活性和疾病活动度强烈降低相关。
  • IFN相关的Galectin-9是接受LEF/HCQ治疗的pSS患者治疗预测和监测的有前景的生物标志物。

研究设计与样本

  • 21例接受LEF/HCQ治疗和8例接受安慰剂治疗的原发性干燥综合征患者,在基线、8、16和24周采血。
  • 在循环单个核细胞和全血中定量五种IFN相关基因RNA表达为基础的IFN特征,全血测MxA蛋白水平,血清定量CXCL10和Galectin-9蛋白水平。
  • 评估应答者与非应答者差异,并用受试者工作特征分析确定基线表达和早期变化(治疗8周后)预测临床终点治疗反应的能力。

主要发现

  • LEF/HCQ治疗24周后外周血单个核细胞和全血IFN特征下降,但IFN特征变化与疾病活动度变化仅弱相关。
  • 与基线IFN特征不同,基线Galectin-9蛋白浓度及循环MxA和Galectin-9的下降与临床反应稳健相关。
  • 血清Galectin-9早期变化最佳预测24周临床反应,曲线下面积0.90。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess to what extent leflunomide (LEF) and hydroxychloroquine (HCQ) therapy in patients with primary Sjögren's syndrome (RepurpSS-I) targets type I IFN-associated responses and to study the potential of several interferon associated RNA-based and protein-based biomarkers to predict and monitor treatment. METHODS: In 21 patients treated with LEF/HCQ and 8 patients treated with placebo, blood was drawn at baseline, 8, 16 and 24 weeks. IFN-signatures based on RNA expression of five IFN-associated genes were quantified in circulating mononuclear cells and in whole blood. MxA protein levels were measured in whole blood, and protein levels of CXCL10 and Galectin-9 were quantified in serum. Differences between responders and non-responders were assessed and receiver operating characteristic analysis was used to determine the capacity of baseline expression and early changes (after 8 weeks of treatment) in biomarkers to predict treatment response at the clinical endpoint. RESULTS: IFN-signatures in peripheral blood mononuclear cell and whole blood decreased after 24 weeks of LEF/HCQ treatment, however, changes in IFN signatures only poorly correlated with changes in disease activity. In contrast to baseline IFN signatures, baseline protein concentrations of galectin-9 and decreases in circulating MxA and Galectin-9 were robustly associated with clinical response. Early changes in serum Galectin-9 best predicted clinical response at 24 weeks (area under the curve 0.90). CONCLUSIONS: LEF/HCQ combination therapy targets type-I IFN-associated proteins that are associated with strongly decreased B cell hyperactivity and disease activity. IFN-associated Galectin-9 is a promising biomarker for treatment prediction and monitoring in pSS patients treated with LEF/HCQ.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Hamkour S, van der Heijden EH, Lopes AP, et al. Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren's syndrome that show potential to predict and monitor clinical response. RMD Open. 2023. PMID: 37532471. doi:10.1136/rmdopen-2023-002979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。